<DOC>
	<DOCNO>NCT01692197</DOCNO>
	<brief_summary>The goal clinical research study learn E7070 combination idarubicin , cytarabine , dexamethasone help control disease patient either AML high-risk MDS relapse . The safety drug combination also study .</brief_summary>
	<brief_title>E7070 , Idarubicin Cytarabine Relapsed AML High-Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description>The Study Drugs : E7070 design stop metabolic ingredient reach cancer cell stop cancer cell divide . Cytarabine design insert DNA ( genetic material cell ) cancer cell stop DNA repairing . Idarubicin design cause break strand DNA ( genetic material cell ) . Dexamethasone corticosteroid similar natural hormone make body . Dexamethasone often give AML patient combination chemotherapy treat cancer . Study Drug Administration : If find eligible take part study , receive E7070 vein 1 hour Day 1 Day 8 ( +/- 2 day Day 8 ) follow idarubicin vein 1 hour Days 9-11 . You also receive cytarabine vein 24 hour day Days 9-12 . If 60 year age old , receive cytarabine Days 9-11 . On day receive cytarabine infusion , also receive dexamethasone vein 30 minute . You receive dexamethasone cytarabine infusion . Each study cycle 28 day . If doctor think benefit take E7070 combination idarubicin , cytarabine , dexamethasone , may receive 2 additional cycle study drug combination . Study Visits : During Cycle 1 , follow test procedure perform : - You ask medication take side effect may . - Blood ( 2 teaspoon ) draw least 1 time every week routine test check liver kidney function . - You bone marrow aspirate Day 28 ( +/- 3 day ) check status disease . You may additional bone marrow aspirate Cycle 2 doctor think necessary . - During Cycle 1 , ECG Day 2 ( +/- 1 day ) Day 8 ( +/- 2 day ) . Treatment cycle beyond Cycle 1 , follow test procedure perform : - You ask medication take side effect may . - Blood ( 2 teaspoon ) draw every 2-4 week routine test . - You bone marrow aspirate check status disease whenever doctor feel necessary . Length Study : If doctor think benefit E7070 combination idarubicin , cytarabine dexamethasone , may receive 2 additional cycle therapy ( total 3 cycle study . ) You take study disease get bad , experience intolerable side effect , study doctor think best interest . End-of-Treatment Visit : At end treatment , blood ( 2 teaspoon ) draw routine test within 30 day ( +/- 5 day ) last dose study drug combination . You also ask side effect may . Long Term Follow-up ( unless start alternative therapy ) : Blood ( 1 tablespoon ) drawn routine test every 2-3 month 2 year unless disease get bad start another treatment . This investigational study . E7070 FDA-approved commercially available use patient AML MDS relapse . Its use study consider investigational . Idarubicin , cytarabine , dexamethasone FDA-approved commercially available use treatment AML . The combination E7070 , idarubicin , cytarabine , dexamethasone study investigational . Up 40 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . All patient histologically cytologically confirm relapsed refractory acute myeloid leukemia ( AML ) [ except acute promyelocytic leukemia ] , highrisk myelodysplastic syndrome ( HRMDS ) ( Int2 high risk IPSS &gt; 10 % blast marrow ) . 2 . Patients must 18 year old . 3 . Patients must performance status 02 ( Zubrod scale ) . 4 . Patients must adequate renal function ( serum creatinine less equal 1.3 mg/dL and/or creatinine clearance &gt; 40 mL/min ) . Patients renal dysfunction due organ infiltration disease may eligible discussion Principal Investigator ( PI ) ( creatinine less equal 2.0 ) , appropriate dose adjustment consider . 5 . Patients must adequate hepatic function ( bilirubin less equal 2.0 mg/dl ; SGOT SGPT less equal 3X ULN reference lab unless due leukemia congenital hemolytic disorder bilirubin ) . Patients hepatic dysfunction ( SGOT/SGPT le equal 5 X ULN ) due organ infiltration disease may eligible discussion PI , appropriate dose adjustment consider . 6 . Patients must normal cardiac ejection fraction 7 . QTc interval &lt; /= 480 msec . 8 . Patients must sign informed consent form indicate aware investigational nature study , keep policy hospital . 9 . Female patient must pregnant lactating . Female patient childbearing potential ( include &lt; 1 year postmenopausal ) male patient must agree use contraception . 1 . Patients must untreated uncontrolled lifethreatening infection . 2 . Patients must receive chemotherapy and/or radiation therapy within 2 week . Hydroxyurea allow 48 hour prior start therapy set rapidly proliferate disease . Use hydroxyurea control proliferative disease allow start day 2 day 7 Cycle 1 . Maximum dose hydroxyurea allow daily 5 gram hydroxyurea must discontinue administration idarubicin cytarabine start . 3 . Any medical condition , include mental illness substance abuse , deem PI likely interfere patient 's ability sign inform consent cooperate participate study interpretation result . 4 . Patients must receive investigational anticancer drug within two week E7070 administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Relapsed Refractory</keyword>
	<keyword>High-Risk Myelodysplastic Syndromes</keyword>
	<keyword>HRMDS</keyword>
	<keyword>E7070</keyword>
	<keyword>Idarubicin</keyword>
	<keyword>Idamycin</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>ARA-C</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine Arabinosine Hydrochloride</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Decadron</keyword>
</DOC>